曾经风光无限的"医美三剑客"，正站在发展的十字路口。在大单品降价潮的冲击下，曾市值巅峰之和近 4000亿元的"医美三剑客"——爱美客、昊海生科、华熙生物，如今陷入了竞争、需求与策略的多重困 境。2024年年报显示，爱美客、昊海生科业绩增速降至个位数，华熙生物净利润更是暴跌超七成，行业 变局之下，它们将如何找到破局之路？ 为寻求新增长，华熙生物在新业务拓展上动作不断，却成效甚微，如在功能性食品领域，消费者认可度 低，市场推广困难。爱美客则试图通过收购韩国医美公司REGEN拓展海外市场，然而1.9亿美元的高额 交易对价及1344.12%的估值溢价，使其未来回报充满不确定性。 爱美客增速骤降，华熙生物业绩"大跳水" 昊海生科2024年财报显示，2024年，昊海生科实现营业收入约为26.98亿元，同比增长1.64%，实现归母 净利润约为4.2亿元，同比增长1.04%。而上年度营收和利润对应增速分别为24.59%和130.58%。 对于业绩下滑，华熙生方面物告诉北京商报记者，公司业绩短期承压，主要受管理变革成本、长期战略 投入、前瞻性研发费用增加以及创新性业务投入、消费品业务调整等多重因素影响，该经营结果是公司 长期持 ...

Core Insights - The beauty and medical aesthetics sectors are increasingly merging, with significant interest from both international giants and local startups, indicating a strong growth trend in this area [1][5][31] - L'Oréal is a leading player in this trend, having made substantial investments and strategic moves to integrate beauty and medical aesthetics [2][10][17] Group 1: Industry Trends - Since 2024, there has been an unusual enthusiasm among beauty companies to enter the medical aesthetics business, with both high-end and budget brands participating [1] - The merger of beauty and medical aesthetics is not a new concept, but it is gaining momentum, with companies like L'Oréal leading the charge [1][5] - The retail sales of cosmetics in China fell by 1.1% in 2024, while the total retail sales of consumer goods grew by 3.5%, highlighting the need for beauty brands to innovate and find new growth avenues [5] Group 2: Company Developments - In 2023, L'Oréal rebranded its active health cosmetics division to the skin science beauty division and launched its core brand, SkinCeuticals, in 2024 [2] - Estee Lauder's Clinique launched a series of medical device products, while Shiseido is set to introduce its first medical beauty brand in China [3] - Domestic brands like Shiseido and Up Beauty are also making strides in the medical aesthetics space, with new product launches and business developments [4] Group 3: Strategic Initiatives - L'Oréal's beauty tech transformation strategy, initiated in 2018, focuses on integrating technology into beauty and medical aesthetics, with significant investments in digital R&D [6][8] - The company has established a comprehensive network for integrating beauty and medical aesthetics, including investments in high-end medical beauty chains and partnerships with biotech firms [17][18] - L'Oréal's SkinCeuticals brand has seen a 9.8% year-on-year growth, reaching €7.03 billion in revenue, making it the fastest-growing segment of the group [10] Group 4: Market Dynamics - The merging of beauty and medical aesthetics allows brands to create a closed-loop product offering, enhancing customer loyalty and repeat purchases [22] - The shift towards medical aesthetics is seen as a necessary strategy to avoid intense competition in traditional beauty markets [19][20] - However, the differing operational models and regulatory requirements between beauty and medical aesthetics present new challenges for companies [24][30]

Core Viewpoint - The integration of AI into the medical beauty industry is reshaping the sector, with significant implications for material research, clinical practices, and consumer services, leading to a transformation from "experience science" to "computational science" [1][2][6]. Group 1: AI Integration in Medical Beauty - Major companies in the medical beauty and cosmetics sectors, such as L'Oréal, Betaini, and Jinbo Biotechnology, have begun deploying AI technologies to enhance their operations [2][7]. - AI is expected to accelerate breakthroughs in material research, replace traditional consultation methods with effect simulation technology, and enable personalized services [2][6]. - The 2024 annual reports indicate that institutional investors are prioritizing "AI empowerment" as a core valuation metric for medical beauty companies [2][6]. Group 2: Investment Trends - Jinbo Biotechnology and Juzhi Biotechnology, which focus on recombinant collagen, have seen significant increases in fund holdings, with Jinbo Biotechnology receiving 35 fund investments, up from single digits a year ago [3][5]. - Jinbo Biotechnology's sales of its recombinant collagen product reached a milestone of one million units, with its stock price increasing by 74.8% over the past year [3][4]. - Meitu, a well-known photo editing company, has also entered the medical beauty space, with its stock price rising by 73.44% in the past year [5]. Group 3: AI's Impact on Industry Practices - AI is revolutionizing various aspects of the medical beauty industry, including clinical diagnosis, consumer services, and material research [6][12]. - AI's application in clinical diagnosis allows for pre-surgical simulations that reduce reliance on physician experience and enhance patient trust [6][12]. - The use of AI in consumer services enables personalized solutions through skin diagnostics and tailored treatment plans, shifting the focus from selling individual products to providing comprehensive solutions [6][12]. Group 4: Future Valuation and Business Models - The competitive landscape and valuation logic of publicly listed medical beauty companies are undergoing significant changes due to AI's pervasive influence [14][16]. - Companies are expected to transition from a focus on individual product sales to a model that emphasizes platform capabilities, data accumulation, and algorithm iteration speed [16]. - The long-term outlook suggests that as AI improves treatment predictions and risk mitigation, the medical beauty industry's business model will evolve towards bundled offerings of "AI solutions + products + services" [16][19]. Group 5: Caution and Challenges - Some companies, like Aimeike, are cautious about AI adoption, focusing instead on upgrading existing product technologies [19]. - The high costs associated with AI development and the potential for regulatory challenges related to AI diagnostics are significant considerations for companies in the sector [19][20]. - The reliance on high-quality data for AI model training poses challenges due to the privacy and fragmentation of medical beauty data [19].

Group 1 - The core viewpoint of the news is that Sihuan Pharmaceutical has achieved a significant breakthrough in the medical aesthetics field with the approval of its self-developed injectable polycaprolactone microsphere facial filler, known as "girl needle" [1][2] - The "girl needle" is a regenerative injectable material that provides immediate filling effects and long-lasting results, with a single treatment lasting over one year [1][2] - The approval of the "girl needle" fills a gap in the company's portfolio of Class III medical devices and positions it among the top three products in the domestic market [2][3] Group 2 - The Chinese market for injectable regenerative materials is projected to grow from approximately 3 billion RMB in 2023 to about 7.2 billion RMB by 2025, with the market share increasing from 11% to 16% [2] - The "girl needle" series has seen over 50% year-on-year sales growth in 2023, indicating strong market demand and positive consumer response [2] - Sihuan Pharmaceutical has a pipeline of additional regenerative materials, including polylactic acid fillers and other innovative products, positioning the company to lead in the rapidly growing regenerative materials market [3]

Core Viewpoint - The independent director's report highlights the company's adherence to regulations and commitment to protecting the interests of all shareholders, particularly minority shareholders, through diligent oversight and participation in key committees [1][8]. Attendance and Voting - The independent director attended all 5 board meetings and 5 shareholder meetings in 2024, voting in favor of all proposals and engaging with minority shareholders [1][2]. Committee Participation - The independent director participated in the Compensation and Assessment Committee once, the Nomination Committee once, and the Audit Committee eight times, including three communications with the accounting firm regarding the audit plan [2][3]. Independent Director Meetings - Several independent director meetings were held to review significant matters, including cash acquisitions and annual profit distribution proposals, all of which were approved without harming the interests of the company or shareholders [4][6][10]. On-Site Inspections - The independent director conducted on-site inspections to understand the company's strategic planning, operational status, and financial conditions, maintaining communication with other board members and management [4][7]. Investor Rights Protection - The independent director reviewed all proposals carefully and exercised voting rights independently and objectively, promoting scientific decision-making within the board [7][8]. Key Focus Areas - The independent director focused on related party transactions, ensuring that all reviewed proposals did not harm the interests of the company or minority shareholders [8][9]. - The company timely prepared and disclosed its annual and quarterly reports, accurately reflecting financial data and operational strategies [9]. - The board approved the reappointment of the accounting firm for the 2024 audit, ensuring compliance with relevant regulations [9][10]. - The board also approved the remuneration plans for directors and senior management, ensuring no detriment to the company or minority shareholders [10].

原国家食品药品监督管理总局新闻宣传司副司长申敬旺在会上指出，医美行业进入强监管时代，合规经 营势在必行。近几年，国家多部门联合执法，严格监管整顿医美市场秩序，在政策指引和行业引导 下，"积极加强行业自律"已成主旋律，进一步加强行业自律、关注品牌美誉，多方共同推动医美行业逐 渐向"规范化"过渡。越来越多部门加入医美行业治理整顿过程中来，全方位监管推动行业规范化发展。 新京报讯（记者王卡拉）近日，第八届全球医学美容创新大会（简称美创会）暨首届中国医美科普大会 在京召开，会上发布《中国医美产业创新蓝皮书（2024）》，全面剖析中国医美产业的创新现状与趋 势，深度探索科技创新在推动产业变革中的关键作用，并提出未来发展的战略方向与具体实施路径。通 过对医美行业核心问题的研究和对未来创新战略的深入分析，为行业的持续健康发展提供了重要的理论 指导与实践参考。 中国医学科学院整形外科医院前任院长祁佐良教授指出，目前医美行业消费降级，医疗美容机构举步维 艰，例如北京医疗美容机构800多家，真正盈利的机构并不多，但是不少投资机构仍然看好医美行业。 医美机构以诚信为本，以医疗服务为本，以品质交付为本，不断地满足医美消费者的需求和服 ...

医美赛道会是资生堂的解药吗？4月1日，北京商报记者获悉，资生堂推出了首个医疗美容品牌 RQPYOLOGY律曜，这意味着资生堂正式通过自有品牌进入医美赛道。当业绩连续多年出现下滑，曾 经风光无比的日妆巨头资生堂也不得不寻找更多新的机会，而市场规模不断扩大的医美赛道被寄予希 望。然而，医美这条赛道已经有了众多玩家，其中就包括资生堂老对手欧莱雅、雅诗兰黛等国际美妆巨 头，如此，资生堂又能有多少机会？ 已备案两款产品 目前市面上关于资生堂旗下律曜品牌的信息并不多，根据为数不多的公开信息，律曜定位高端医美，品 牌理念是将皮肤护理与医学美学相融合，旨在满足那些对专业美容效果有追求，同时渴望享受高端体验 的消费者。据了解，该品牌即将在中国市场上市。 北京商报记者从国家药监局的备案信息官网了解到，目前律曜已经成功备案了两款产品，分别为律曜智 熠焕光透白精华乳、律曜智驭防晒乳。另根据媒体公开报道，资生堂就新品牌将与国内多地的医疗诊所 及医院展开合作，通过医研共创推动产品的持续迭代。目前律曜已经注册了官方公众号，注册时间为 2024年9月11日，认证主体为资生堂(中国)投资有限公司，该品牌在服务号简介为"高端术研，科技美 肤" ...

Core Viewpoint - The annual financial report of Four Rings Pharmaceutical reveals strong growth in both its medical aesthetics and innovative drug segments, indicating a potential for value reassessment in the market. Financial Highlights - Medical aesthetics business achieved revenue of 744 million yuan, a year-on-year increase of 65.4%, driven by new product approvals and improved profit margins [3]. - Innovative drug and other pharmaceutical revenues reached approximately 57.6 million yuan, up 388.1% year-on-year, with the approval of the new drug Annelaz sodium contributing to this growth [4]. - Research and development expenditures were about 474 million yuan, a decrease of 18.0% year-on-year, while maintaining high investment levels and progressing well in clinical trials [5]. - The company reported a strong cash flow position with net cash inflow from operating activities of 244 million yuan and total cash and cash equivalents nearing 4 billion yuan [7]. Medical Aesthetics Business - The medical aesthetics sector is positioned for certain growth, supported by industry expansion, product diversity, and channel coverage [10]. - The Chinese medical aesthetics market is projected to reach 638.2 billion yuan by 2030, with a compound annual growth rate of 14.5% from 2021 to 2030 [11]. - The company has a comprehensive product line covering over 60 products in the medical aesthetics space, addressing a full lifecycle of consumer needs [12]. - The company has received approvals for seven new products, enhancing its product matrix and potentially increasing overall profit margins [13]. Innovative Drug Business - The innovative drug segment is entering a critical phase, with significant revenue growth driven by the approval of Annelaz sodium [16]. - The company is advancing multiple core products into late-stage clinical trials, which are expected to yield substantial returns in the coming years [17]. - The innovative drug pipeline includes promising candidates targeting large market opportunities, such as breast cancer and non-small cell lung cancer [20]. Value Catalysts - The company has three main catalysts for valuation enhancement: product launches, pipeline advancements, and potential spin-offs [21]. - The medical aesthetics and diabetes drug segments are expected to see significant volume growth, contributing to robust revenue increases [23]. - The company is actively pursuing global market expansion, particularly in South America and the Middle East, to enhance its revenue streams [23]. - The spin-off of Xuan Zhu Bio is anticipated to create an independent valuation system for the innovative drug segment, potentially increasing overall market capitalization [29]. Market Position - The company's current market valuation is low, with a market capitalization of 5.2 billion HKD, which is below the industry average [31]. - The company possesses substantial hard assets exceeding 7 billion yuan, providing a solid safety net for its market valuation [32].

Core Insights - The company achieved a revenue of CNY 3.03 billion in 2024, representing a growth of 5.5%, and a net profit of CNY 1.96 billion, up by 5.3% [1] - The company maintained stable profitability with a gross margin of 94.6% and a net margin of 64.7% for the year [1] - In Q4 2024, the company reported a revenue of CNY 650 million, a decrease of 7.0%, and a net profit of CNY 370 million, down by 15.5% [1] Revenue and Profit Analysis - Revenue from solution products was CNY 1.74 billion, growing by 4.4% - Revenue from gel products reached CNY 1.22 billion, increasing by 5.0% - Revenue from facial implant lines was approximately CNY 6.804 million, up by 15.0% - Other revenues, including cosmetics, amounted to CNY 59.192 million, a significant increase of 68.5% [1] R&D and Acquisition Strategy - The company increased its R&D expense ratio to 10.0%, up by 1.3 percentage points, indicating a focus on product pipeline development [2] - The company announced plans to acquire 85% of South Korean REGEN for USD 19 million, which is expected to significantly contribute to revenue and profit by 2026 [2] - The acquisition includes two listed products, AestheFill and PowerFill, which are anticipated to enhance the company's market position [2] Earnings Forecast and Valuation - Revenue projections for 2025 and 2026 are CNY 3.30 billion and CNY 3.60 billion, reflecting year-on-year growth of 9.2% and 9.1% respectively [3] - Net profit forecasts for the same years are CNY 2.02 billion and CNY 2.18 billion, with growth rates of 3.1% and 7.7% [3] - The target price for the company is set at CNY 299.47 per share, based on a price-to-earnings ratio of 45x for 2025 and 42x for 2026 [3]

Investment Rating - The report maintains an "Outperform" rating for the company [1][2][7] Core Views - The company achieved steady growth in 2024, with revenue of Rmb 3.03 billion (+5.5%) and net profit of Rmb 1.96 billion (+5.3%), maintaining a gross profit margin of 94.6% [3][11] - The company is focusing on overseas mergers and acquisitions, particularly the proposed acquisition of REGEN in South Korea, which is expected to significantly contribute to revenue and profits in 2026 [4][16] Financial Performance - Revenue and profit growth for 2024: Revenue of Rmb 3,026 million, net profit of Rmb 1,958 million, with a gross profit margin of 94.6% [3][11] - Q4 2024 performance showed a revenue decline of 7.0% to Rmb 650 million and a net profit decline of 15.5% to Rmb 370 million [12] - Revenue by product category: Solution-based products Rmb 1.74 billion (+4.4%), Gel-based products Rmb 1.22 billion (+5.0%), Facial implant threads Rmb 6.804 million (+15.0%), Other revenue Rmb 59.192 million (+68.5%) [13][14] Research and Development - Increased R&D investment with a ratio of 10.0% in 2024, focusing on new product pipelines and clinical trials [4][15] - The company has received clinical trial approvals for several new products, indicating a commitment to innovation [15] Acquisition Strategy - The proposed acquisition of REGEN for US$190 million is expected to enhance the company's product offerings and production capacity, with the second factory in South Korea expected to start production in Q2 2025 [4][16] - The target company reported revenue of Rmb 72.23 million and net profit of Rmb 29.5 million from January to September 2024 [16] Earnings Forecast and Valuation - Revenue projections for 2025 and 2026 are Rmb 3.30 billion and Rmb 3.60 billion, respectively, with year-on-year growth of 9.2% and 9.1% [5][17] - The target price is set at Rmb 299.47 per share, corresponding to a P/E ratio of 45x for 2025 and 42x for 2026 [7][17]